| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | DANAZOL | Dopamine Transporter | 89% | 6.842uM | 5.436uM | View | 
          
            
                | arachidonate 15-lipoxygenase, second type | BETA-ESTRADIOL | Lipoxygenase 15-LO | 89% | 11.295uM | NoneNone | View | 
          
            
                | arachidonate 15-lipoxygenase | BETA-ESTRADIOL | Lipoxygenase 15-LO | 89% | 11.295uM | NoneNone | View | 
          
            
                | arachidonate 15-lipoxygenase | BETA-ESTRADIOL | Lipoxygenase 15-LO | 89% | 11.295uM | NoneNone | View | 
          
            
                | nuclear receptor subfamily 3, group C, member 1 | ETHINYLESTRADIOL | Glucocorticoid | 89% | 1.71uM | .777uM | View | 
          
            
                | solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 | 4-OCTYLPHENOL | Dopamine Transporter | 89% | 8.491uM | 6.746uM | View | 
          
            
                | prostaglandin-endoperoxide synthase 2 | PHENOTHIAZINE | Cyclooxygenase COX-2 | 89% | .532uM | NoneNone | View | 
          
            
                | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | PHENOTHIAZINE | Cyclooxygenase COX-2 | 89% | .532uM | NoneNone | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 4 | TIRILAZAD | Calcium Channel Type L, Benzothiazepine | 89% | 2.694uM | 2.395uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H, member 8 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 6 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 7 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 2 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 5 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 3 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 4 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 1 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | potassium voltage-gated channel, subfamily H (eag-related), member 1 | MITOXANTRONE | Potassium Channel HERG | 89% | 3.5849uM | 2.937uM | View | 
          
            
                | Cytochrom P450-1A2 monooxygenase | BW-723C86 | CYP450-1A2 Inhibition | 89% | .8738uM | NoneNone | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 8 | PERHEXILINE | Calcium Channel Type L, Benzothiazepine | 89% | 1.0569uM | .9394uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 7 | PERHEXILINE | Calcium Channel Type L, Benzothiazepine | 89% | 1.0569uM | .9394uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 6 | PERHEXILINE | Calcium Channel Type L, Benzothiazepine | 89% | 1.0569uM | .9394uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 5 | PERHEXILINE | Calcium Channel Type L, Benzothiazepine | 89% | 1.0569uM | .9394uM | View | 
          
            
                | thromboxane A synthase 1 | GRAMICIDIN | Thromboxane Synthetase | 88% | .774uM | NoneNone | View | 
          
            
                | thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) | GRAMICIDIN | Thromboxane Synthetase | 88% | .774uM | NoneNone | View | 
          
            
                | adrenergic receptor, alpha 2a | METHAPYRILENE | Adrenergic alpha2A | 88% | 1.165uM | .437uM | View | 
          
            
                | Sigma-2 Receptor | BROMHEXINE | Sigma2 | 88% | .059uM | .036uM | View | 
          
            
                | arachidonate 15-lipoxygenase, second type | FERULIC ACID | Lipoxygenase 15-LO | 88% | 3.975uM | NoneNone | View | 
          
            
                | arachidonate 15-lipoxygenase | FERULIC ACID | Lipoxygenase 15-LO | 88% | 3.975uM | NoneNone | View | 
          
            
                | arachidonate 15-lipoxygenase | FERULIC ACID | Lipoxygenase 15-LO | 88% | 3.975uM | NoneNone | View | 
          
            
                | histamine receptor H 2 | BENZTROPINE | Histamine H2 | 88% | 1.206uM | 1.185uM | View | 
          
            
                | sodium channel, voltage-gated, type VII, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | amiloride-sensitive cation channel 5, intestinal | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type III, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type VIII, alpha polypeptide | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type XI, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type I, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type 10, alpha polypeptide | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, alpha polypeptide | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type V, alpha polypeptide | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type II, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 gamma | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type 2, alpha 1 polypeptide | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type XI, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1, gamma | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1, delta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type X, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type IX, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage gated, type VIII, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type VII, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type III, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type II, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type II, alpha 2 | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type I, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel associated protein 1 | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel associated protein 2 | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type III, beta | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | BENZTROPINE | Sodium Channel, Site 2 | 88% | 1.68uM | 1.533uM | View | 
          
            
                | dopamine receptor D4 | HALOPERIDOL | Dopamine D4.2 | 87% | .563uM | .198uM | View | 
          
            
                | adrenergic receptor, alpha 2b | HALOPERIDOL | Adrenergic alpha2B | 87% | 1.354uM | .618uM | View | 
          
            
                | dopamine receptor D1A | GENTIAN VIOLET | Dopamine D1 | 87% | 3.102uM | 1.551uM | View | 
          
            
                | cholinergic receptor, muscarinic 4 | MIANSERIN | Muscarinic M4 | 87% | 2.066uM | .288uM | View | 
          
            
                | histamine receptor H 2 | MIANSERIN | Histamine H2 | 87% | 1.008uM | .992uM | View | 
          
            
                | Cytochrom P450-2D6 monooxygenase | LYSERGOL | CYP450-2D6 Inhibition | 87% | 1uM | NoneNone | View | 
          
            
                | dopamine receptor 2 | METHYSERGIDE | Dopamine D2L | 87% | .807uM | .269uM | View | 
          
            
                | mitogen activated protein kinase 14 | 1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE | Protein Serine/Threonine Kinase, p38alpha | 87% | .746uM | NoneNone | View | 
          
            
                | mitogen-activated protein kinase 14 | 1-(2-METHOXYBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE | Protein Serine/Threonine Kinase, p38alpha | 87% | .746uM | NoneNone | View | 
          
            
                | prostaglandin-endoperoxide synthase 2 | ETODOLAC | Cyclooxygenase COX-2 | 87% | .561uM | NoneNone | View | 
          
            
                | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | ETODOLAC | Cyclooxygenase COX-2 | 87% | .561uM | NoneNone | View | 
          
            
                | 5-hydroxytryptamine (serotonin) receptor 2B | LORATADINE | Serotonin 5-HT2B | 86% | .245uM | .156uM | View | 
          
            
                | mitogen activated protein kinase 14 | 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE | Protein Serine/Threonine Kinase, p38alpha | 86% | .537uM | NoneNone | View | 
          
            
                | mitogen-activated protein kinase 14 | 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE | Protein Serine/Threonine Kinase, p38alpha | 86% | .537uM | NoneNone | View | 
          
            
                | A3 adenosine receptor | 1-NAPHTHYL ISOTHIOCYANATE | Adenosine A3 | 86% | 6.1uM | 3.448uM | View | 
          
            
                | acetylcholinesterase (YT blood group) | IRINOTECAN | Acetylcholinesterase | 86% | 1.827uM | NoneNone | View | 
          
            
                | collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase | IRINOTECAN | Acetylcholinesterase | 86% | 1.827uM | NoneNone | View | 
          
            
                | acetylcholinesterase | IRINOTECAN | Acetylcholinesterase | 86% | 1.827uM | NoneNone | View | 
          
            
                | dopamine receptor D1A | KETOTIFEN | Dopamine D1 | 86% | .872uM | .436uM | View | 
          
            
                | opioid receptor, kappa 1 | SAQUINAVIR | Opiate kappa | 86% | 6.951uM | 2.78uM | View | 
          
            
                | Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) | RITONAVIR | CYP450-2C9 Inhibition | 86% | .016uM | NoneNone | View | 
          
            
                | cytochrome P450, family 2, subfamily C, polypeptide 9 | RITONAVIR | CYP450-2C9 Inhibition | 86% | .016uM | NoneNone | View | 
          
            
                | 5-hydroxytryptamine (serotonin) receptor 3a | OLANZAPINE | Serotonin 5-HT3 | 86% | 1.316uM | .296uM | View | 
          
            
                | 5-hydroxytryptamine (serotonin) receptor 3b | OLANZAPINE | Serotonin 5-HT3 | 86% | 1.316uM | .296uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel associated protein 1 | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel associated protein 2 | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type III, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type IX, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type VII, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | amiloride-sensitive cation channel 5, intestinal | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type III, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type VIII, alpha polypeptide | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type XI, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type I, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type 10, alpha polypeptide | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, alpha polypeptide | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type V, alpha polypeptide | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type II, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 gamma | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type 2, alpha 1 polypeptide | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type XI, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1, gamma | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1, delta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type X, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type IX, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage gated, type VIII, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type VII, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type III, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type II, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type II, alpha 2 | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type I, beta | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | ORPHENADRINE | Sodium Channel, Site 2 | 86% | 2.492uM | 2.274uM | View | 
          
            
                | Cytochrom P450-2D6 monooxygenase | BUPIVACAINE HYDROCHLORIDE | CYP450-2D6 Inhibition | 86% | .4uM | NoneNone | View | 
          
            
                | calcium channel, voltage-dependent, beta 1 subunit | U-78517F | Calcium Channel Type L, Dihydropyridine | 86% | 1.659uM | 1.066uM | View | 
          
            
                | calcium channel, voltage-dependent, beta 2 subunit | TAMOXIFEN | Calcium Channel Type L, Dihydropyridine | 85% | 8.585uM | 5.519uM | View | 
          
            
                | Cytochrom P450-1A2 monooxygenase | NIFEDIPINE | CYP450-1A2 Inhibition | 85% | .3uM | NoneNone | View | 
          
            
                | adrenergic receptor, alpha 2a | ERGONOVINE | Adrenergic alpha2A | 85% | 1.68uM | .63uM | View | 
          
            
                | dopamine receptor 2 | ERGONOVINE | Dopamine D2L | 85% | .552uM | .184uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 8 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 7 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 6 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 5 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 4 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 3 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 2 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, gamma subunit 1 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, beta 4 subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, beta 3 subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, beta 2 subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, L type, alpha 1S subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, alpha 1F subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, L type, alpha 1D subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, L type, alpha 1C subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, beta 1 subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, L type, alpha 1E subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, N type, alpha 1B subunit | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | calcium channel, voltage-dependent, alpha2/delta subunit 1 | CISAPRIDE | Calcium Channel Type L, Benzothiazepine | 85% | .802uM | .713uM | View | 
          
            
                | adrenergic receptor, alpha 2b | CISAPRIDE | Adrenergic alpha2C | 85% | .78uM | .113uM | View | 
          
            
                | adrenergic receptor, alpha 2c (Non-specific probe) | CISAPRIDE | Adrenergic alpha2C | 85% | .78uM | .113uM | View | 
          
            
                | 5-hydroxytryptamine (serotonin) receptor 2C | ATROPINE | Serotonin 5-HT2C | 85% | 1.012uM | .53uM | View | 
          
            
                | Sigma-2 Receptor | CLEMASTINE | Sigma2 | 85% | .728uM | .448uM | View | 
          
            
                | adrenergic receptor, alpha 2a | CLOZAPINE | Imidazoline I2, Central | 85% | .384uM | .256uM | View | 
          
            
                | adrenergic receptor, alpha 2c (Non-specific probe) | CLOZAPINE | Imidazoline I2, Central | 85% | .384uM | .256uM | View | 
          
            
                | Protein-tyrosine kinase, Fyn | S(-)-CARBIDOPA | Protein Tyrosine Kinase, Fyn | 85% | 3.731uM | NoneNone | View | 
          
            
                | opioid receptor, sigma 1 | MOSAPRIDE | Sigma1 | 85% | .3056uM | .1284uM | View | 
          
            
                | dopamine receptor D3 | MEPAZINE | Dopamine D3 | 85% | 2.006uM | .681uM | View | 
          
            
                | solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | 2-ACETYLAMINOFLUORENE | Serotonin Transporter | 85% | 6.053uM | 3.216uM | View | 
          
            
                | Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) | 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE | CYP450-2C9 Inhibition | 85% | 2uM | NoneNone | View | 
          
            
                | cytochrome P450, family 2, subfamily C, polypeptide 9 | 1-(2-FLUOROBENZOYL)-4-(PHENYLMETHYL)-PIPERIDINE | CYP450-2C9 Inhibition | 85% | 2uM | NoneNone | View | 
          
            
                | sodium channel, voltage-gated, type IV, alpha | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type III, alpha | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type II, beta | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type II, alpha 2 | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type I, beta | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | PUROMYCIN | Sodium Channel, Site 2 | 12% | NoneNone | NoneNone | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel associated protein 1 | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel associated protein 2 | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type III, beta | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type IX, alpha | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, voltage-gated, type VII, alpha | MEPAZINE | Sodium Channel, Site 2 | 85% | 2.521uM | 2.3uM | View | 
          
            
                | sodium channel, nonvoltage-gated 1 alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type X, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type IX, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage gated, type VIII, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type VII, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type III, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type II, beta | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type II, alpha 2 | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type I, beta | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type IV, beta | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel associated protein 1 | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel associated protein 2 | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type III, beta | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type I, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | sodium channel, voltage-gated, type IX, alpha | PAROXETINE | Sodium Channel, Site 2 | 85% | 2.69uM | 2.454uM | View | 
          
            
                | Sigma-2 Receptor | PROCHLORPERAZINE | Sigma2 | 85% | .676uM | .416uM | View |